Hematologic Malignancies and Cellular Therapy

Danielle Marie Brander, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box 3872 DUMC, Durham, NC 27710
Phone (919) 684-8166
Email address danielle.brander@duke.edu
In Their Words

Education and Training

  • Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
  • M.D., Duke University School of Medicine, 2007

Grants

Publications

Mato, AR, Roeker, LE, Allan, JN, Pagel, JM, Brander, DM, Hill, BT, Cheson, BD, Furman, RR, Lamanna, N, Tam, CS, Handunnetti, S, Jacobs, R, Lansigan, F, Bhavsar, E, Barr, PM, Shadman, M, Skarbnik, AP, Goy, A, Beach, DF, Svoboda, J, Pu, JJ, Sehgal, AR, Zent, CS, Tuncer, HH, Schuster, SJ, Pickens, PV, Shah, NN, Rhodes, J, Ujjani, CS, and Nabhan, C. "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial." American Journal of Hematology 93, no. 11 (November 2018): 1394-1401.

PMID
30132965
Full Text

Mato, AR, Thompson, M, Allan, JN, Brander, DM, Pagel, JM, Ujjani, CS, Hill, BT, Lamanna, N, Lansigan, F, Jacobs, R, Shadman, M, Skarbnik, AP, Pu, JJ, Barr, PM, Sehgal, AR, Cheson, BD, Zent, CS, Tuncer, HH, Schuster, SJ, Pickens, PV, Shah, NN, Goy, A, Winter, AM, Garcia, C, Kennard, K, Isaac, K, Dorsey, C, Gashonia, LM, Singavi, AK, Roeker, LE, Zelenetz, A, Williams, A, Howlett, C, Weissbrot, H, Ali, N, Khajavian, S, Sitlinger, A, Tranchito, E, Rhodes, J, Felsenfeld, J, Bailey, N, Patel, B, Burns, TF, Yacur, M, Malhotra, M, Svoboda, J, Furman, RR, and Nabhan, C. "Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States." Haematologica 103, no. 9 (September 2018): 1511-1517.

PMID
29880613
Full Text

Mato, AR, Samp, JC, Gauthier, G, Terasawa, E, and Brander, DM. "Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies." Cancer Biology & Therapy 19, no. 7 (July 3, 2018): 636-643.

Full Text

Mato, AR, Nabhan, C, Thompson, MC, Lamanna, N, Brander, DM, Hill, B, Howlett, C, Skarbnik, A, Cheson, BD, Zent, C, Pu, J, Kiselev, P, Goy, A, Claxton, D, Isaac, K, Kennard, KH, Timlin, C, Landsburg, D, Winter, A, Nasta, SD, Bachow, SH, Schuster, SJ, Dorsey, C, Svoboda, J, Barr, P, and Ujjani, CS. "Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis." Haematologica 103, no. 5 (May 2018): 874-879.

PMID
29419429
Full Text

Burris, HA, Flinn, IW, Patel, MR, Fenske, TS, Deng, C, Brander, DM, Gutierrez, M, Essell, JH, Kuhn, JG, Miskin, HP, Sportelli, P, Weiss, MS, Vakkalanka, S, Savona, MR, and O'Connor, OA. "Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study." The Lancet. Oncology 19, no. 4 (April 2018): 486-496.

PMID
29475723
Full Text

Thompson, M, Brander, D, Nabhan, C, and Mato, A. "Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents." Jama Oncology 4, no. 3 (March 1, 2018): 394-394.

Full Text

Wierda, WG, Byrd, JC, Abramson, JS, Bhat, S, Bociek, G, Brander, D, Brown, J, Chanan-Khan, A, Coutre, SE, Davis, RS, Fletcher, CD, Hill, B, Kahl, BS, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Lancet, J, Ma, S, Malek, S, Mosse, C, Shadman, M, Siddiqi, T, Stephens, D, Wagner, N, Zelenetz, AD, Dwyer, MA, and Sundar, H. "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 11 (November 2017): 1414-1427.

PMID
29118233
Full Text

Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, A-L, Claxton, DF, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ, and Nabhan, C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of Oncology : Official Journal of the European Society for Medical Oncology 28, no. 5 (May 2017): 1050-1056.

PMID
28453705
Full Text

Seymour, JF, Ma, S, Brander, DM, Choi, MY, Barrientos, J, Davids, MS, Anderson, MA, Beaven, AW, Rosen, ST, Tam, CS, Prine, B, Agarwal, SK, Munasinghe, W, Zhu, M, Lash, LL, Desai, M, Cerri, E, Verdugo, M, Kim, SY, Humerickhouse, RA, Gordon, GB, Kipps, TJ, and Roberts, AW. "Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study." The Lancet. Oncology 18, no. 2 (February 2017): 230-240.

PMID
28089635
Full Text

Brander, DM. "Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?." British journal of haematology 176, no. 3 (February 2017): 337-340.

PMID
27984636
Full Text

Pages